Is Compass Therapeutics, Inc. (CMPX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.7% / 30% | 12.9% / 30% | 0.0% / 30% | 858.82% / 5% | ✗ NOT HALAL |
| DJIM | 0.7% / 33% | 12.9% / 33% | 0.0% / 33% | 858.82% / 5% | ✗ NOT HALAL |
| MSCI | 4.7% / 33% | 90.3% / 33% | 0.0% / 33% | 858.82% / 5% | ✗ NOT HALAL |
| S&P | 0.7% / 33% | 12.9% / 33% | 0.0% / 33% | 858.82% / 5% | ✗ NOT HALAL |
| FTSE | 4.7% / 33% | 90.3% / 33% | 0.0% / 50% | 858.82% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -41.3% | |
| Return on Assets (ROA) | -25.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$49M |
| Free Cash Flow | -$49M |
| Total Debt | $10M |
| Debt-to-Equity | 5.0 |
| Current Ratio | 15.0 |
| Total Assets | $220M |
Price & Trading
| Last Close | $5.33 |
| 50-Day MA | $5.88 |
| 200-Day MA | $4.36 |
| Avg Volume | 2.2M |
| Beta | 1.3 |
|
52-Week Range
$1.33
| |
About Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Compass Therapeutics, Inc. (CMPX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Compass Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Compass Therapeutics, Inc.'s debt ratio?
Compass Therapeutics, Inc.'s debt ratio is 0.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 4.7%.
What are Compass Therapeutics, Inc.'s key financial metrics?
Compass Therapeutics, Inc. has a market capitalization of $938M. Return on equity stands at -41.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.